RNA
Atrium Therapeutics, Inc.
Price Chart
Latest Quote
$12.66
+0.18 (+1.44%)
Current Price
| Previous Close | $12.48 |
| Open | $12.83 |
| Day High | $12.96 |
| Day Low | $12.29 |
| Volume | 274,781 |
Stock Information
| Shares Outstanding | 17.11M |
| Total Debt | $2.68M |
| Cash Equivalents | $267.85M |
| Revenue | $36.68M |
| Net Income | $-58.69M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $216.56M |
| EPS (TTM) | $-5.02 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-48.61M |
| Sales | $36.68M |
| Income | $-58.69M |
| Book/sh | $13.69 |
| Cash/sh | $15.66 |
Financial Ratios
| Quick Ratio | 12.91 |
| Current Ratio | 13.04 |
| Debt/Eq | 1.15 |
Returns & Margins
| Gross Margin | -32.91% |
| Operating Margin | -88.01% |
| Profit Margin | -159.99% |
Ownership
| Insider Ownership | 4.27% |
| Institutional Ownership | 87.99% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.16 |
| P/S | 5.90 |
| P/B | 0.93 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $25.00 |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| RSI | 42.53 |
| ATR | nan |
| Shares Float | 15.76M |
| Short Ratio | 17.66 |
| Rel Volume | 1.39 |
Performance History
| Week | +1.85% |
| Month | -2.24% |
| Quarter | -0.24% |
| YTD | -14.17% |
| 10 Years | -14.17% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $12.66 | 294,100 |
| 2026-06-17 | $12.48 | 190,300 |
| 2026-06-16 | $12.61 | 160,500 |
| 2026-06-15 | $12.75 | 261,500 |
| 2026-06-12 | $12.37 | 103,600 |
| 2026-06-11 | $12.43 | 328,700 |
| 2026-06-10 | $11.67 | 136,600 |
| 2026-06-09 | $11.76 | 201,700 |
| 2026-06-08 | $11.55 | 126,100 |
| 2026-06-05 | $11.80 | 209,400 |
| 2026-06-04 | $12.30 | 126,100 |
| 2026-06-03 | $12.17 | 150,100 |
| 2026-06-02 | $12.25 | 180,700 |
| 2026-06-01 | $12.68 | 209,600 |
| 2026-05-29 | $13.00 | 321,300 |
| 2026-05-28 | $13.36 | 345,200 |
| 2026-05-27 | $13.00 | 169,200 |
| 2026-05-26 | $13.06 | 170,900 |
| 2026-05-22 | $13.09 | 292,200 |
| 2026-05-21 | $13.04 | 252,400 |
| 2026-05-20 | $12.72 | 168,100 |
| 2026-05-19 | $12.95 | 273,100 |
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
đ° Latest News
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation
Simply Wall St. âĸ 2026-05-28T10:24:57Z
Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline
Simply Wall St. âĸ 2026-03-19T17:04:03Z
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
Pharma Voice âĸ 2026-03-19T08:00:00Z
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal
GuruFocus.com âĸ 2026-03-17T12:09:55ZSector Update: Health Care Stocks Advance Late Afternoon
MT Newswires âĸ 2026-03-16T19:42:50ZAvidity (RNA) Moves Date for Shareholder Vote on Novartis Merger
Insider Monkey âĸ 2026-02-27T21:05:40Z
European Stocks Mostly Higher in Friday Trading; French GDP Growth Slows, Inflation Rises
MT Newswires âĸ 2026-02-27T16:51:17ZAtrium spins out of Avidity, aiming to target rare heart diseases with RNA
BioPharma Dive âĸ 2026-02-27T12:58:42Z
Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-01-22T12:10:00Z
JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals
Pharmaceutical Technology âĸ 2026-01-13T16:43:05Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $18,618,000 | $10,897,000 | $9,764,000 | $9,224,000 |
| Operating Revenue | $18,618,000 | $10,897,000 | $9,764,000 | $9,224,000 |
| Expenses | ||||
| Total Expenses | $95,432,000 | $24,115,000 | $16,150,000 | $188,137,000 |
| Other Income Expense | $-12,000 | $2,000 | $1,000 | $-57,000 |
| Other Non Operating Income Expenses | $-12,000 | $2,000 | $1,000 | $-57,000 |
| Operating Expense | $95,432,000 | $24,115,000 | $16,150,000 | $188,137,000 |
| General And Administrative Expense | $41,676,000 | $4,916,000 | $3,497,000 | $37,733,000 |
| Interest Expense | - | - | - | $0 |
| Net Non Operating Interest Income Expense | - | - | - | $4,975,000 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-76,684,000 | $-25,122,000 | $-6,385,000 | $-173,995,000 |
| Normalized Income | $-76,684,000 | $-25,122,000 | $-6,385,000 | $-173,995,000 |
| Net Income From Continuing And Discontinued Operation | $-76,684,000 | $-25,122,000 | $-6,385,000 | $-173,995,000 |
| Total Operating Income As Reported | $-76,814,000 | $-13,218,000 | $-6,386,000 | $-178,913,000 |
| Net Income Common Stockholders | $-76,684,000 | $-25,122,000 | $-6,385,000 | $-173,995,000 |
| Net Income | $-76,684,000 | $-25,122,000 | $-6,385,000 | $-173,995,000 |
| Net Income Including Noncontrolling Interests | $-76,684,000 | $-25,122,000 | $-6,385,000 | $-173,995,000 |
| Net Income Continuous Operations | $-76,684,000 | $-25,122,000 | $-6,385,000 | $-173,995,000 |
| Pretax Income | $-76,826,000 | $-13,216,000 | $-6,385,000 | $-173,995,000 |
| Operating Income | $-76,814,000 | $-13,218,000 | $-6,386,000 | $-178,913,000 |
| Net Interest Income | - | - | - | $4,975,000 |
| Interest Income | - | - | - | $4,975,000 |
| Interest Income Non Operating | - | - | - | $4,975,000 |
| Per Share | ||||
| Diluted EPS | $-2.89 | $-1.47 | $-0.37 | $-3.34 |
| Basic EPS | $-2.89 | $-1.47 | $-0.37 | $-3.34 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-76,491,000 | $-13,046,000 | $-6,248,000 | $-177,526,000 |
| Reconciled Depreciation | $323,000 | $172,000 | $138,000 | $1,387,000 |
| EBITDA (Bullshit earnings) | $-76,491,000 | $-13,046,000 | $-6,248,000 | $-177,526,000 |
| EBIT | $-76,814,000 | $-13,218,000 | $-6,386,000 | $-178,913,000 |
| Diluted Average Shares | $17,105,643 | $17,124,000 | $17,124,000 | $52,162,000 |
| Basic Average Shares | $17,105,643 | $17,114,000 | $17,114,000 | $52,162,000 |
| Diluted NI Availto Com Stockholders | $-76,684,000 | $-25,122,000 | $-6,385,000 | $-173,995,000 |
| Tax Provision | $-142,000 | $11,906,000 | $0 | - |
| Research And Development | $53,756,000 | $19,199,000 | $12,653,000 | $150,404,000 |
| Selling General And Administration | $41,676,000 | $4,916,000 | $3,497,000 | $37,733,000 |
| Other Gand A | $41,676,000 | $4,916,000 | $3,497,000 | $37,733,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $207,287,000 | $-61,108,000 | $-70,619,000 | $578,075,000 |
| Total Assets | $278,353,000 | $7,186,000 | $10,293,000 | $638,800,000 |
| Total Non Current Assets | $5,508,000 | $6,703,000 | $9,437,000 | $15,858,000 |
| Current Assets | $272,845,000 | $483,000 | $856,000 | $622,942,000 |
| Other Current Assets | $1,310,000 | - | - | $12,215,000 |
| Prepaid Assets | $1,535,000 | $483,000 | $105,000 | $8,340,000 |
| Cash Cash Equivalents And Short Term Investments | $270,000,000 | - | - | $610,727,000 |
| Cash And Cash Equivalents | $270,000,000 | - | - | $340,396,000 |
| Receivables | - | $0 | $751,000 | $3,875,000 |
| Accounts Receivable | - | $0 | $751,000 | $2,364,000 |
| Other Non Current Assets | - | - | - | $849,000 |
| Accrued Interest Receivable | - | - | - | $1,511,000 |
| Debt | ||||
| Total Debt | $3,672,000 | $6,801,000 | $9,852,000 | $10,687,000 |
| Current Debt And Capital Lease Obligation | $3,672,000 | $3,844,000 | $3,639,000 | $3,105,000 |
| Long Term Debt And Capital Lease Obligation | - | $2,957,000 | $6,213,000 | $7,582,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $71,066,000 | $68,294,000 | $80,912,000 | $60,725,000 |
| Total Non Current Liabilities Net Minority Interest | $29,265,000 | $41,492,000 | $47,111,000 | $8,817,000 |
| Other Non Current Liabilities | $574,000 | $574,000 | - | - |
| Non Current Deferred Liabilities | $28,691,000 | $37,961,000 | $40,898,000 | $1,235,000 |
| Current Liabilities | $41,801,000 | $26,802,000 | $33,801,000 | $51,908,000 |
| Current Deferred Liabilities | $21,639,000 | $20,987,000 | $28,161,000 | $5,041,000 |
| Payables And Accrued Expenses | $13,343,000 | $1,725,000 | $1,153,000 | $32,572,000 |
| Payables | $4,398,000 | $532,000 | $498,000 | $4,637,000 |
| Accounts Payable | $4,398,000 | $532,000 | $498,000 | $4,637,000 |
| Equity | ||||
| Common Stock Equity | $207,287,000 | $-61,108,000 | $-70,619,000 | $578,075,000 |
| Total Equity Gross Minority Interest | $207,287,000 | $-61,108,000 | $-70,619,000 | $578,075,000 |
| Stockholders Equity | $207,287,000 | $-61,108,000 | $-70,619,000 | $578,075,000 |
| Other Equity Interest | - | $-61,108,000 | $-70,619,000 | - |
| Gains Losses Not Affecting Retained Earnings | - | - | - | $-2,698,000 |
| Other Equity Adjustments | - | - | - | $-2,698,000 |
| Retained Earnings | - | - | - | $-358,544,000 |
| Other | ||||
| Ordinary Shares Number | $17,105,643 | $17,105,643 | $17,105,643 | $69,768,000 |
| Share Issued | $17,105,643 | $17,105,643 | $17,105,643 | $69,768,000 |
| Tangible Book Value | $207,287,000 | $-61,108,000 | $-70,619,000 | $578,075,000 |
| Invested Capital | $207,287,000 | $-61,108,000 | $-70,619,000 | $578,075,000 |
| Working Capital | $231,044,000 | $-26,319,000 | $-32,945,000 | $571,034,000 |
| Capital Lease Obligations | $3,672,000 | $6,801,000 | $9,852,000 | $10,687,000 |
| Total Capitalization | $207,287,000 | $-61,108,000 | $-70,619,000 | $578,075,000 |
| Additional Paid In Capital | $207,270,000 | - | - | $939,310,000 |
| Capital Stock | $17,000 | - | - | $7,000 |
| Common Stock | $17,000 | - | - | $7,000 |
| Non Current Deferred Revenue | $28,691,000 | $37,961,000 | $40,898,000 | $1,235,000 |
| Current Deferred Revenue | $21,639,000 | $20,987,000 | $28,161,000 | $5,041,000 |
| Current Capital Lease Obligation | $3,672,000 | $3,844,000 | $3,639,000 | $3,105,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,147,000 | $246,000 | $848,000 | $11,190,000 |
| Current Accrued Expenses | $8,945,000 | $1,193,000 | $655,000 | $27,935,000 |
| Net PPE | $5,508,000 | $6,703,000 | $9,437,000 | $15,009,000 |
| Accumulated Depreciation | $-2,844,000 | $-1,234,000 | $-885,000 | $-3,120,000 |
| Gross PPE | $8,352,000 | $7,937,000 | $10,322,000 | $18,129,000 |
| Leases | $0 | $288,000 | $288,000 | $249,000 |
| Other Properties | $6,581,000 | $7,649,000 | $10,034,000 | $15,972,000 |
| Machinery Furniture Equipment | $1,771,000 | $0 | - | $1,908,000 |
| Properties | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | - | $2,957,000 | $6,213,000 | $7,582,000 |
| Other Short Term Investments | - | - | - | $270,331,000 |
| Preferred Stock | - | - | - | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-42,574,000 | $-22,819,000 | $56,070,000 | $-139,091,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-41,129,000 | $-22,553,000 | $56,390,000 | $-136,268,000 |
| Cash Flow From Continuing Operating Activities | $-41,129,000 | $-22,553,000 | $56,390,000 | $-136,268,000 |
| Operating Gains Losses | $140,000 | $204,000 | $195,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,445,000 | $-266,000 | $-320,000 | $-2,823,000 |
| Investing Cash Flow | $-1,445,000 | $-266,000 | $-320,000 | $-189,955,000 |
| Cash Flow From Continuing Investing Activities | $-1,445,000 | $-266,000 | $-320,000 | $-189,955,000 |
| Financing Activities | ||||
| Financing Cash Flow | $42,574,000 | $22,819,000 | $-56,070,000 | $346,171,000 |
| Cash Flow From Continuing Financing Activities | $42,574,000 | $22,819,000 | $-56,070,000 | $346,171,000 |
| Net Other Financing Charges | $42,574,000 | $22,819,000 | $-56,070,000 | - |
| Issuance Of Capital Stock | - | - | - | $344,779,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $344,779,000 |
| Common Stock Issuance | - | - | - | $344,779,000 |
| Cash Dividends Paid | - | - | - | - |
| Other | ||||
| End Cash Position | $0 | $0 | $0 | $340,647,000 |
| Beginning Cash Position | $0 | $0 | $0 | $320,699,000 |
| Net PPE Purchase And Sale | $-1,445,000 | $-266,000 | $-320,000 | $-2,823,000 |
| Purchase Of PPE | $-1,445,000 | $-266,000 | $-320,000 | $-2,823,000 |
| Change In Working Capital | $-200,000 | $-12,890,000 | $59,935,000 | $7,067,000 |
| Change In Other Working Capital | $-12,017,000 | $-13,807,000 | $59,454,000 | $-5,120,000 |
| Change In Other Current Liabilities | $0 | $574,000 | $0 | $-1,762,000 |
| Change In Other Current Assets | $-1,310,000 | $0 | - | - |
| Change In Payables And Accrued Expense | $14,179,000 | $-30,000 | $-836,000 | $20,565,000 |
| Change In Accrued Expense | $10,451,000 | $-64,000 | $-790,000 | $2,250,000 |
| Change In Payable | $3,728,000 | $34,000 | $-46,000 | $18,315,000 |
| Change In Account Payable | $3,728,000 | $34,000 | $-46,000 | $18,315,000 |
| Change In Prepaid Assets | $-1,052,000 | $-378,000 | $-69,000 | $-6,616,000 |
| Change In Receivables | $0 | $751,000 | $1,386,000 | - |
| Changes In Account Receivables | $0 | $751,000 | $1,386,000 | - |
| Other Non Cash Items | $572,000 | $204,000 | - | $2,749,000 |
| Stock Based Compensation | $7,679,000 | $3,177,000 | $2,507,000 | $27,139,000 |
| Deferred Tax | $-142,000 | $11,906,000 | $0 | - |
| Deferred Income Tax | $-142,000 | $11,906,000 | $0 | - |
| Depreciation Amortization Depletion | $323,000 | $172,000 | $138,000 | $1,387,000 |
| Depreciation And Amortization | $323,000 | $172,000 | $138,000 | $1,387,000 |
| Depreciation | $323,000 | $172,000 | $138,000 | $1,387,000 |
| Gain Loss On Sale Of PPE | $140,000 | $0 | $195,000 | - |
| Net Income From Continuing Operations | $-49,501,000 | $-25,122,000 | $-6,385,000 | $-173,995,000 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Changes In Cash | - | - | - | $19,948,000 |
| Proceeds From Stock Option Exercised | - | - | - | $1,392,000 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Net Investment Purchase And Sale | - | - | - | $-187,132,000 |
| Sale Of Investment | - | - | - | $168,705,000 |
| Purchase Of Investment | - | - | - | $-355,837,000 |
| Amortization Of Securities | - | - | - | $-615,000 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-20